After accounting for exceptional items, the company's adjusted profit stood at Rs 13 crore. Biocon attributed last year’s higher profitability to a one-time gain from Bicara and proceeds from Biocon ...

The eligible products have been split into three categories. Category 1: Biopharmaceuticals (includes biologics, biosimilars and vaccines); complex generic drugs; patented drugs or drugs whose ...

Pli­ant Ther­a­peu­tics has of­fi­cial­ly dis­con­tin­ued a mid-stage study of its chron­ic lung dis­ease treat­ment, less than a month af­ter the tri­al’s safe­ty board rec­om ...

RAMSEY, N.J. (AP) — RAMSEY, N.J. (AP) — Adma Biologics Inc. (ADMA) on Monday reported fourth-quarter net income of $111.9 million, after reporting a loss in the same period a year earlier.

The NASDAQ composite index has been scorching hot since the fall of 2022, as the Magnificent 7 drove the markets to all-time highs. However, that came to a screeching halt in February, when it ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...

If standard antihistamines fail to provide relief, guideline-directed escalation, including dose increases and biologic therapies, may be necessary. Anxiety and depression are common due to ...

AbbVie is joining the industry’s rush to develop new obesity medicines, announcing Monday a deal with Denmark-based Gubra to license a drug that could compete with experimental therapies being ...

And they’re pretty good. But it’s interesting. This the first time in my life I’m a consumer of a– we have consumer electronics. Now we have consumer biologics. And so that was shocking in a good way ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.17 per share a year ago.